What are Praxis Precision Medicines, Inc.'s total assets?

Praxis Precision Medicines, Inc. (PRAX) holds $1.5B in total assets, up 205.0% year over year.

How much debt does Praxis Precision Medicines, Inc. have?

Praxis Precision Medicines, Inc. carries $1.4M in total debt against $1.4B of shareholders' equity, a debt-to-equity ratio of 0.00.

How much cash does Praxis Precision Medicines, Inc. have?

Praxis Precision Medicines, Inc. holds $536.7M in cash and equivalents.

Can Praxis Precision Medicines, Inc. cover its short-term obligations?

Its current ratio is 15.88 — current assets exceed current liabilities.

Where does Praxis Precision Medicines, Inc.'s balance sheet data come from?

Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Praxis Precision Medicines, Inc. PRAX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$536.75M+50.0%	$357.75M+139%	$149.94M-5.0%	$157.83M-4.9%	$165.98M-23.1%
Short-term investments	$250.53M+3.5%	$242M+106%	$117.63M-18.2%	$143.86M-11.4%	$162.42M-8.3%
Restricted cash	——	——	——	——	——
Prepaid expenses and other current assets	$34.48M+18.3%	$29.16M-0.8%	$29.38M+14.3%	$25.71M+1.9%	$25.24M+5.0%
Trading assets	$250.53M+3.5%	$242M+106%	$117.63M-18.2%	$143.86M-11.4%	$162.42M-8.3%
Total current assets	$797.77M+30.6%	$610.91M+123%	$273.84M-10.7%	$306.58M-8.1%	$333.58M-17.5%
Property and equipment, net	$170K+15.6%	$147K-15.5%	$174K-32.6%	$258K+4.5%	$247K+7.4%
Operating lease right-of-use assets	$1.32M+1,335%	$92K-74.6%	$362K-42.2%	$626K-29.0%	$882K-22.0%
Available-for-sale securities	$660.94M+102%	$326.76M+168%	$122.01M-16.1%	$145.37M+0.9%	$144.03M+87.1%
Total assets	$1.46B+55.7%	$937.91M+137%	$396.39M-12.5%	$452.83M-5.4%	$478.74M-0.9%
Accounts payable	$31.16M+26.5%	$24.63M-20.1%	$30.82M+6.9%	$28.83M+25.9%	$22.91M+82.9%
Accrued expenses	$17.65M-49.6%	$35.03M+62.0%	$21.63M+13.7%	$19.02M+22.3%	$15.55M-34.6%
Operating lease liabilities, current	$1.44M+1,205%	$110K-74.8%	$436K-42.3%	$755K-29.2%	$1.07M-15.3%
Total current liabilities	$50.24M-15.9%	$59.77M+13.0%	$52.88M+8.8%	$48.61M+23.0%	$39.52M+5.3%
Operating Lease Liabilities (Total)	——	——	——	——	——
Total liabilities	$50.24M-15.9%	$59.77M+13.0%	$52.88M+8.8%	$48.61M+23.0%	$39.52M+4.9%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	150M0.0%	150M0.0%	150M0.0%	150M0.0%	150M+1,071,329%
Additional paid-in capital	$2.64B+31.1%	$2.02B+44.7%	$1.39B+0.9%	$1.38B+2.7%	$1.34B+4.9%
Retained earnings	-$1.23B-8.1%	-$1.14B-8.5%	-$1.05B-7.6%	-$977.16M-7.9%	-$906.04M-8.3%
Accumulated other comprehensive income (loss)	-$1.59M-383%	$563K+12.6%	$500K+26.6%	$395K-40.1%	$659K+0.8%
Treasury stock	0—	0—	0—	0—	0—
Total stockholders' equity	$1.41B+60.6%	$878.14M+156%	$343.51M-15.0%	$404.22M-8.0%	$439.21M-1.4%
Total liabilities and stockholders' equity	$1.46B+55.7%	$937.91M+137%	$396.39M-12.5%	$452.83M-5.4%	$478.74M-0.9%
AFS and Trading Securities - Unrealized Loss Position Fair Value	——	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	——	——	——	——	——
Cash Cash Equivalents And Short Term Investments	——	——	——	——	——
Short- term Investments	——	——	——	——	——
Available-for-Sale Securities (Non-Current)	——	——	——	——	——
Net Investment in Lease	$1.32M+1,335%	$92K-74.6%	$362K-42.2%	$626K-29.0%	$882K-22.0%
Long-term marketable securities	$911.47M+60.3%	$568.76M+366%	$122.01M-16.1%	$145.37M+0.9%	$144.03M+87.1%
Long- term Investments	——	——	——	——	——
Operating lease right-of-use assets	$1.32M+1,335%	$92K-74.6%	$362K-42.2%	$626K-29.0%	$882K-22.0%
Operating Lease Right-of-Use Assets in Other Assets	$1.32M+1,335%	$92K-74.6%	$362K-42.2%	$626K-29.0%	$882K-22.0%
Other Commercial Liabilities	$17.65M-49.6%	$35.03M+62.0%	$21.63M+13.7%	$19.02M+22.3%	$15.55M-34.6%
Accrued Liabilities, Current	$17.65M-49.6%	$35.03M+62.0%	$21.63M+13.7%	$19.02M+22.3%	$15.55M-34.6%
Total debt	$1.4M+1,173%	$110K-74.8%	$436K-42.3%	$755K-29.2%	$1.07M-22.1%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	27.9M+10.6%	25.2M+19.0%	21.2M+0.6%	21M+3.4%	20.3M+4.7%
Common Stock Shares Outstanding	——	——	——	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$15K0.0%	$15K+7.1%	$14K0.0%	$14K0.0%	$14K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	——	——	——	——	——
Number of Exercisable Options	——	——	——	——	——
Number of Vested and Expected to Vest Options	——	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	1.9M+3.7%	1.9M-9.4%	2.1M-1.5%	2.1M+2.5%	2.1M+13.3%
Shares Reserved for Future Issuance Under Stock Plans	6.7M+26.4%	5.3M+2.0%	5.2M-0.4%	5.2M-0.8%	5.3M+52.1%
Weighted Average Exercise Price of Outstanding Options	$101.08+12.6%	$89.80+3.0%	$87.20+0.7%	$86.63-1.4%	$87.82-3.3%
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——	——
Components	——	——	——	——	——
Accrued external research and development expenses	$12.94M-9.4%	$14.29M-8.5%	$15.62M+2.3%	$15.28M+31.3%	$11.64M-12.9%
Accrued personnel-related expenses	$2.99M-84.0%	$18.71M+408%	$3.68M+40.1%	$2.63M+22.3%	$2.15M-77.1%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$660.94M+102%	$326.76M+168%	$122.01M-16.1%	$145.37M+0.9%	$144.03M+87.1%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$250.53M+3.5%	$242M+106%	$117.63M-18.2%	$143.86M-11.4%	$162.42M-8.3%
Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure	$1.16B+50.1%	$771.06M+144%	$315.67M-16.0%	$375.58M-6.2%	$400.5M+0.4%
Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax	——	——	——	——	——
Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax	——	——	——	——	——
Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost	$1.16B+50.4%	$770.49M+144%	$315.17M-16.0%	$375.19M-6.2%	$399.84M+0.4%
Common stock, capital shares reserved for future issuance	$6.73M+26.4%	$5.32M+2.0%	$5.22M-0.4%	$5.24M-0.8%	$5.28M+52.1%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$150M0.0%	$150M0.0%	$150M0.0%	$150M0.0%	$150M0.0%
Common stock, shares issued (in shares)	$27.86M+10.6%	$25.2M+19.0%	$21.17M+0.6%	$21.04M+3.4%	$20.34M+4.7%
Common Stock, Shares, Outstanding	$27.86M+10.6%	$25.2M+19.0%	$21.17M+0.6%	$21.04M+3.4%	$20.34M+4.7%
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions	——	——	——	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	——	——	——	——	——
Number of performance obligations	——	——	——	——	——
Number of platforms	——	——	——	——	——
Number of product candidates	——	——	——	——	——
Other accrued liabilities	$1.72M-15.5%	$2.03M-12.6%	$2.32M+108%	$1.11M-36.7%	$1.76M+70.1%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$1.95M+3.7%	$1.88M-9.4%	$2.07M-1.5%	$2.1M+2.5%	$2.05M+13.3%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$101.08+12.6%	$89.8+3.0%	$87.2+0.7%	$86.63-1.4%	$87.82-3.3%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——
Treasury stock, shares (in shares)	$0—	$0—	$0—	$0—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Praxis Precision Medicines, Inc.'s total assets?: Praxis Precision Medicines, Inc. (PRAX) holds $1.5B in total assets, up 205.0% year over year.
How much debt does Praxis Precision Medicines, Inc. have?: Praxis Precision Medicines, Inc. carries $1.4M in total debt against $1.4B of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Praxis Precision Medicines, Inc. have?: Praxis Precision Medicines, Inc. holds $536.7M in cash and equivalents.
Can Praxis Precision Medicines, Inc. cover its short-term obligations?: Its current ratio is 15.88 — current assets exceed current liabilities.
Where does Praxis Precision Medicines, Inc.'s balance sheet data come from?: Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.